Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01607086 | Compare the Properties and Characteristics of an Investigational Formulation of Lamotrigine With Placebo | PHASE1 | COMPLETED | 24 | — | — | Jul 11, 2008 | Jul 18, 2008 | Aug 3, 2017 | 1 | United Kingdom |
| Arm | Type | Description |
|---|---|---|
| Group 1 | EXPERIMENTAL | To receive the sequence of investigational products in the order of AB where A is cherry lamotrigine ODT and B is cherry placebo. |
| Group 2 | EXPERIMENTAL | To receive the sequence of investigational products in the order of BA where A is cherry lamotrigine ODT and B is cherry placebo. |
| Name | Type | Description |
|---|---|---|
| Cherry lamotrigine ODT | DRUG | 25mg, taken orally on one study visit |
| Cherry Placebo | DRUG | Taken orally on one study visit |
Inclusion Criteria: A subject will be eligible for inclusion in this study only if all of the following criteria apply: * Healthy as judged by the responsible physician or designee. No clinically significant abnormality identified on the medical or laboratory evaluation. A subject with a clinical ...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Teladoc Health, Inc. | TDOC | 1 | NA | Undisclosed |
| Unity Health Toronto | UBX | 2 | NA | Undisclosed |